SILO | Jotup

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

Retrieved on:

Friday, September 30, 2022

Silo Pharmas common stock began trading on the Nasdaq Capital Market under the symbol SILO on September 27, 2022.

Key Points:

Silo Pharmas common stock began trading on the Nasdaq Capital Market under the symbol SILO on September 27, 2022.
The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silo Pharma, were $5,750,000 million.
Silo Pharma intends to use the net proceeds from the offering for product development, marketing, and working capital and general corporate purposes.
A portion of the proceeds may also be used for acquisitions of complementary businesses, technologies, or other assets.

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

Retrieved on:

Tuesday, September 27, 2022

The gross proceeds to Silo Pharma from this offering are expected to be $5,000,000, before deducting the underwriting discount and other estimated offering expenses payable by Silo Pharma.

Key Points:

The gross proceeds to Silo Pharma from this offering are expected to be $5,000,000, before deducting the underwriting discount and other estimated offering expenses payable by Silo Pharma.
Silo Pharma intends to use the net proceeds from the offering for product development, marketing, and working capital and general corporate purposes.
A portion of the proceeds may also be used for acquisitions of complementary businesses, technologies, or other assets.
As a result of the offering, the Companys common stock will become listed on the Nasdaq Capital Market and will trade under the ticker symbol SILO beginning September 27, 2022.

UNITE Monaco 2022: Worlds leading investors, game changing companies and high profile individuals gather to discuss the fast changing global business landscape

Retrieved on:

Thursday, June 16, 2022

DUBAI, United Arab Emirates, June 16, 2022 /PRNewswire-PRWeb/ -- Unite Monaco 2022 edition, created by The Private Investment Group, held during Monaco Grand Prix, May 26-29, had a clear mission of bringing together an innovative approach, global industries, countries, and high-profile individuals from the investment, finance, social and business world, for 4 days on Azzura II, 165ft Superyacht in Port Hercule.

Key Points:

The award is designed to bring increased visibility and broader recognition to the sustainable, philanthropic, and positive societal impact initiatives of the Formula 1 teams.
UNITE Monaco was also joined by the incredible team at Proper 12 Whiskey.
ID is a global BioTech company with offices in the U.S., Canada, and Tokyo focused on next-gen wearable biotech.
UNITE Journey will continue with UNITE Abu Dhabi, on a superyacht parked in Yas Marina during the Abu Dhabi Grand Prix on 17-22 November 2022.

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Retrieved on:

Wednesday, October 27, 2021

This agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University Irving Medical Center.

Key Points:

This agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University Irving Medical Center.
Denny and her team are focusing their efforts on the molecular mechanisms underlying learning and memory, including diseases such as Alzheimers disease.
Eric Weisblum, CEO of Silo Pharma statedWe are excited to partner with Dr. Denny and Columbia University, a world-renowned institution that is at the forefront of research and development in this area.
To be able to bring hope and possibly a therapeutic to patients suffering from Alzheimers disease is an exciting proposition for Silo Pharma.

Redbox Expands Ad Supported Video on Demand (AVOD) Streaming Service With Hundreds of Hours of Content From Award-Winning Oscilloscope Laboratories

Retrieved on:

Wednesday, September 15, 2021

Redbox, a leading entertainment company, today announced it has partnered with film production and distributor Oscilloscope Laboratories to bring hundreds of hours of content to its rapidly growing Ad Supported Video on Demand (AVOD) streaming service.

Key Points:

Redbox, a leading entertainment company, today announced it has partnered with film production and distributor Oscilloscope Laboratories to bring hundreds of hours of content to its rapidly growing Ad Supported Video on Demand (AVOD) streaming service.
Oscilloscope Laboratories is well-known for producing high-quality films many of which have won or have been nominated for Academy and Golden Globe Awards.
"We're thrilled to bring hundreds of hours of their movies to our Redbox customers completely free."
Redbox Entertainment, a new content acquisition and production division, has further transformed Redbox into a multi-channel content provider.